Belge Bilgin Gokce, Lucien-Matteoni Fabrice, Chaudhuri Aadel A, Orme Jacob J, Childs Daniel S, Muniz Miguel, Li Gary G, Chauhan Pradeep S, Lee SeungBaek, Gupta Sounak, Thorpe Matthew P, Johnson Derek R, Johnson Geoffrey B, Kendi Ayse Tuba, Sartor Oliver
Department of Radiology, Mayo Clinic Rochester, MN, USA.
Department of Urology, Mayo Clinic Rochester, MN, USA.
Cancer Treat Rev. 2025 May;136:102941. doi: 10.1016/j.ctrv.2025.102941. Epub 2025 Apr 9.
Neuroendocrine prostate cancer (NEPC) is rare at the time of initial diagnosis but much more common in patients treated with the combination of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) such as abiraterone and enzalutamide. NEPC is typically characterized by the loss of prostate-specific membrane antigen (PSMA) expression while exhibiting variable neuroendocrine markers. Recent advancements in nuclear medicine have provided a promising avenue for the development of molecular imaging techniques and targeted therapies tailored to NEPC. This review examines the current and future role of theranostics in the diagnosis and management of NEPC and explores potential future directions in this rapidly evolving field.
神经内分泌前列腺癌（NEPC）在初诊时较为罕见，但在接受雄激素剥夺疗法（ADT）与雄激素受体通路抑制剂（ARPI）联合治疗的患者中更为常见，如阿比特龙和恩杂鲁胺。NEPC的典型特征是前列腺特异性膜抗原（PSMA）表达缺失，同时呈现出多种神经内分泌标志物。核医学的最新进展为开发针对NEPC的分子成像技术和靶向治疗提供了一条充满希望的途径。本综述探讨了诊疗一体化在NEPC诊断和管理中的当前及未来作用，并探索了这一快速发展领域潜在的未来方向。
